Appraising the Use of JAK Inhibitors in Treating Myelofibrosis
JAK inhibitors have been the mainstay treatment for patients who have been diagnosed with myelofibrosis.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- ASH 2024: New Research, Data Drive Progress in Myelofibrosis
- Primary Myelofibrosis
- Extended Access of Momelotinib in Adults With Myelofibrosis
- The Ongoing Challenges of Managing Cytopenic Myelofibrosis in 2025: The Emergence of Non‑JAK Inhibitor Therapies
- Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis